Mezigdomide

DRUG18 trials

Sponsors

Karyopharm Therapeutics Inc, Celgene, Bristol-Myers Squibb, Abdullah Khan, City of Hope Medical Center

Conditions

Acute LeukemiaAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaExtramedullary Disease in Multiple MyelomaHepatic ImpairmentKMT2A-rearrangedLeukemiaMixed Phenotype Acute Leukemia

Phase 1

Selinexor and Backbone Treatments of Multiple Myeloma Patients

RecruitingNCT02343042

Karyopharm Therapeutics IncMultiple Myeloma

Start: 2015-10-31End: 2027-04-30Target: 300Updated: 2025-12-22

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

CompletedNCT05707390

Bristol-Myers SquibbHepatic Impairment

Start: 2023-02-20End: 2023-09-13Updated: 2024-02-07

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

RecruitingNCT05981209

Abdullah KhanRecurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2023-12-21End: 2026-12-31Target: 27Updated: 2026-02-02

Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma

RecruitingNCT06048250

City of Hope Medical CenterMultiple Myeloma

Start: 2024-04-09End: 2026-03-21Target: 15Updated: 2025-05-01

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma

WithdrawnNCT06050512

Kathleen DorritieRelapsed and Refractory Multiple Myeloma

Start: 2023-10-02End: 2026-10-31Updated: 2024-11-19

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06121843

Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyMultiple Myeloma

Start: 2024-02-22End: 2028-08-01Target: 147Updated: 2026-02-18

A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruitingNCT06163898

CelgeneMultiple Myeloma

Start: 2024-02-27End: 2025-05-30Target: 156Updated: 2025-04-04

A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment

CompletedNCT06318676

CelgeneRenal Impairment

Start: 2024-03-21End: 2024-11-15Updated: 2025-06-04

Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06645678

YOUNGIL KOHRelapsed Refractory Multiple Myeloma (RRMM)

Start: 2024-11-26End: 2027-10-01Target: 75Updated: 2025-12-03

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

RecruitingNCT06988488

CelgeneMultiple Myeloma

Start: 2025-10-07End: 2027-06-03Target: 62Updated: 2026-02-02

Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma

Not yet recruitingNCT07032714

Massachusetts General HospitalRelapsed Refractory Multiple Myeloma (RRMM)

Start: 2025-12-16End: 2028-07-01Target: 25Updated: 2025-06-26

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

RecruitingNCT07105059

Memorial Sloan Kettering Cancer CenterMultiple Myeloma

Start: 2025-08-08End: 2028-08-08Target: 18Updated: 2026-02-09

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

Not yet recruitingNCT07355335

Massachusetts General HospitalKMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML

Start: 2026-07-09End: 2028-01-01Target: 24Updated: 2026-01-22

A Study of Revumenib and Mezigdomide in People With Leukemia

RecruitingNCT07356154

Memorial Sloan Kettering Cancer CenterAcute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia +5

Start: 2026-01-16End: 2029-01-16Target: 52Updated: 2026-01-21

Phase 2

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

RecruitingNCT06627751

Roswell Park Cancer InstituteExtramedullary Disease in Multiple Myeloma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma

Start: 2025-05-01End: 2030-05-01Target: 28Updated: 2026-01-12

Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

RecruitingNCT05519085

CelgeneRelapsed or Refractory Multiple Myeloma

Start: 2022-09-20End: 2033-11-30Target: 810Updated: 2026-03-24

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

Active, not recruitingNCT05552976

Bristol-Myers SquibbRelapsed or Refractory Multiple Myeloma

Start: 2023-01-10End: 2029-07-25Updated: 2026-04-01

Unknown Phase

Expanded Access for Mezigdomide

Bristol-Myers Squibb

Updated: 2025-12-11

Related Papers

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Blood2025-11-03

Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood2025-11-03

Trial in progress: A phase 1b/2a study to evaluate mezigdomide in combination with elranatamab in patients with relapsed/refractory multiple myeloma

Blood2025-11-03

Selinexor, mezigdomide, and dexamethasone in patients with Relapsed/Refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results

Blood2025-11-03

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Blood Advances2024-12-035 citations

Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Blood2024-11-051 citations

Selinexor Combined with Daratumumab, Thalidomide, and Dexamethasone in Patients with First Relapsed Multiple Myeloma: A Single-Arm, Multicenter, Prospective Study

Blood2024-11-05

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Frontiers in Oncology2024-05-178 citations

Selinexor Combined Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma with Extramedullary Disease(EMD) or High-Risk Cytogenetics

Blood2023-11-02

A PHASE 3, TWO-STAGE, RANDOMIZED STUDY OF MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VERSUS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): SUCCESSOR-2

Hematology Transfusion and Cell Therapy2023-10-011 citations

Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator

CPT Pharmacometrics & Systems Pharmacology2023-09-133 citations

P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

HemaSphere2023-08-011 citations

PB2096: SELINEXOR COMBINED REGIMEN FOR MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE(EMD)

HemaSphere2023-08-01

Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies.

2023-06-0511 citations

A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2.

Journal of Clinical Oncology2023-06-016 citations

Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment.

Journal of Clinical Oncology2023-06-014 citations

Efficacy and safety of 40 mg vs 60 mg once weekly selinexor in combination with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2023-06-01

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Blood2022-11-154 citations

Selinexor-Based Regimens in Patients with Multiple Myeloma after Prior Anti-B-Cell Maturation Antigen Treatment

Blood2021-11-056 citations

Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)

Blood2021-11-052 citations

13 more papers not shown